Financial Data and Key Metrics Changes - For Q1 2020, the company reported a net loss attributable to common shareholders of approximately $5.2 million or $0.03 per share, compared to a net loss of approximately $4.3 million or $0.04 per share in the same quarter last year [39] - Research and development expenses increased to approximately $4.1 million in Q1 2020 from approximately $2.3 million in the same quarter last year, primarily due to higher clinical development expenses [40] - General and administrative expenses rose to approximately $2.3 million in Q1 2020 from approximately $1.8 million in the previous year, mainly due to higher employee compensation costs [40] - The company ended Q1 2020 with approximately $71.2 million in cash, cash equivalents, and marketable securities, up from approximately $27.8 million at year-end 2019, bolstered by net proceeds of approximately $46.7 million from a public offering [41] Business Line Data and Key Metrics Changes - The company is focused on advancing its clinical stage candidates, particularly MAT9001 and MAT2203, with significant resources allocated to these drugs [70] - MAT9001 is positioned as a next-generation prescription-only omega-3 therapy, with enrollment for the ENHANCE-IT study expected to resume in June 2020 [15] - MAT2203, an oral formulation of amphotericin B, is being developed for the treatment of cryptococcal meningitis, with enrollment for the EnACT trial anticipated to resume in June [25] Market Data and Key Metrics Changes - The global invasive antifungal market is valued at several billion dollars, with MAT2203 expected to capture a significant share if approved [30] - The antifungal drug market is currently limited by the toxicity of existing treatments, creating an opportunity for MAT2203 to provide a safer oral alternative [72] Company Strategy and Development Direction - The company remains committed to its mission of developing therapies for critical needs, with a strong balance sheet allowing for continued progress despite the challenges posed by the COVID-19 pandemic [14] - The focus remains on advancing both MAT9001 and MAT2203, with the potential for increased attention and support for infectious disease treatments due to the pandemic [70] - The company is also exploring collaborations with big pharma to leverage their expertise and resources for further development [36] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to navigate the challenges posed by COVID-19, highlighting the importance of maintaining business continuity and prioritizing safety [10] - The company anticipates several meaningful inflection points in the coming quarters, with a cash runway extending into the first half of 2023 [41][42] - Management emphasized the importance of the ENHANCE-IT study for differentiating MAT9001 from competitors and the potential for MAT2203 to address significant unmet medical needs [62][75] Other Important Information - The company has implemented various mitigation strategies to ensure business continuity during the pandemic, including remote work measures and pausing clinical trial enrollments [11][12] - The company is preparing for an end-of-phase meeting with the FDA to discuss the phase 3 protocol for MAT9001, aiming for approval to enter phase 3 in the first half of 2021 [87] Q&A Session Summary Question: Update on MAT2501 - Management indicated that advancing MAT2501 will depend on support from the Cystic Fibrosis Foundation, with ongoing formulation work being conducted [46][48] Question: Expansion of ENHANCE-IT sites - The decision to expand sites was made to ensure timely data delivery and to mitigate risks associated with COVID-19 [50][52] Question: Impact of recent patent wins for Vascepa - Management stated that the patent situation for Vascepa does not impact MAT9001 directly, and the market for omega-3 therapies continues to expand [60][62] Question: Market opportunity for antifungal treatments - Management highlighted the significant unmet need in the antifungal market and the potential for MAT2203 to address this need effectively [68][72] Question: ENHANCE-IT's influence on Phase 3 protocol - ENHANCE-IT is primarily aimed at differentiation for commercialization and will provide additional safety data for submission [79][80]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38022 MATINAS BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware No. 46-3011414 (State or other ...

Matinas BioPharma Holdings, Inc. (NYSE:MTNB) Q4 2019 Results Earnings Conference Call March 9, 2020 8:00 AM ET Company Participants Peter Vozzo - Investor Relations Jerry Jabbour - Chief Executive Officer Terry Ferguson - Chief Medical Officer Terry Matkovits - Chief Development Officer Keith Kucinski - Chief Financial Officer. Conference Call Participants Robert Hazlett - BTIG Edward Tenthoff - Piper Sandler Greg Fraser - SunTrust Jason McCarthy - Maxim Group Operator Greetings, and welcome to the Matinas ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38022 MATINAS BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware No. 46-3011414 (State or other juris ...

Matinas BioPharma Holdings, Inc. (NYSE:MTNB) Q3 2019 Earnings Conference Call November 13, 2019 8:00 AM ET Company Participants Peter Vozzo - Investor Relations Jerry Jabbour - Chief Executive Officer Keith Kucinski - Chief Financial Officer Terry Ferguson - Chief Medical Officer Conference Call Participants Jason McCarthy - Maxim Group Gregg Gilbert - SunTrust Robert Hazlett - BTIG Chad Messer - Needham & Company Jerry Isaacson - Roth Capital Operator Greetings, and welcome to the Matinas BioPharma Third ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38022 MATINAS BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware No. 46-3011414 (State or ot ...

www.matinasbiopharma.com NYSE AMERICAN: MTNB Corporate Presentation September 2019 Forward-Looking Statement This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including those relating to the Company's product development, clinical and regulatory timelines, market opportunity, cash flow and other statements that are predictive in nature, that depend upon or refer to future events or conditions. All statements other than stateme ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38022 MATINAS BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware No. 46-3011414 (State or other j ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38022 MATINAS BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware No. 46-3011414 (State or other ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38022 MATINAS BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware No. 46-3011414 (State or other juris ...